BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
NEWARK, N.J., April 8, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology-based company, today announced the appointment of Michael D. Francis , J.D., as a new member to its Board of Directors.
Mr. Francis is a graduate of the Wharton School of Business, University of Pennsylvania and received his Juris Doctorate from Rutgers University, School of Law. He has been an attorney in the state of New Jersey since 1971. Throughout his career, Mr. Francis has held numerous board appointments within the health care industry. From 1978 to present, he has been Director of the Daughters of Israel Geriatric Center, and held former posts as Treasurer, President and Vice President.
Previously, Mr. Francis was Chairman of Board for the following organizations: Newark Beth Israel Medical Center from 1980 to 1998; United Way of Essex and West Hudson from 1986 to 1990; and Beth Health Care Foundation from 1988 to 1999. His executive management experience includes Chairman and CEO of the Planned Companies from 1989 to 2008 and President of All State Cleaning Contractors from 1971 to 1985. He was CEO of Atlantic Building Maintenance Corp. from 1971 to 1985, where he was responsible for managing the aforementioned companies, providing multifaceted building maintenance services with in excess of 1,000 employees.
"We are honored to welcome Mr. Francis to our Board. He is not only a significant investor but also a long time advisor to the company and advocate of our innovative technology. He is an experienced successful entrepreneur and health care advocate, who has won numerous awards by serving his local community and government," stated Stephen J. Browand, Chairman and CEO of BioNeutral Group, Inc. who went on to say, "His legal acumen and health care advisory experience will provide additional, valuable insight as we move forward with commercializing our newly EPA-approved Ygiene® Hospital-Grade products."
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. AutoNeutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene®-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and will soon be available for sale in the United States.
North 6th Agency
Investor Relations Contact:
ProActive Capital Resources Group, LLC
FOR THE COMPANY:
Stephen J. Browand
BioNeutral Group, Inc.
SOURCE BioNeutral Group, Inc.
More by this Source
BioNeutral Gains Initial Market Acceptance
Feb 25, 2013, 09:00 ET
BioNeutral appoints Chairman of its Audit and Executive Compensation Committees
Dec 17, 2012, 16:12 ET
BioNeutral Enters Into Equity Purchase Agreement With Southridge Partners II
Dec 13, 2012, 15:48 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.